Skip to content
The COVID-19 pandemic has translated into staggering gains for some biotech stocksthis year, rendering valuations unattractive even after the positive financial impact of the viral outbreak is taken into consideration. Valuation Bubble In Play: It's a no-brainer that some biotechs that are working on coronavirus vaccines or treatments are making heady gains.Novavax, Inc. (NASDAQ: NVAX), Moderna Inc (NASDAQ: MRNA) and Inovio Pharmaceuticals Inc (NASDAQ: INO) are among the COVID-19-levered biotechs that are riding the wave of pandemic news. Other stocks like Zoom Video Communications Inc (NASDAQ: ZM) and Teladoc Health Inc (NYSE: TDOC) are capitalizing on the restrictions put in place to contain the spread of the virus. Data Source: Yahoo Finance and YChartsNovavax Gets Fresh Lease of Life: Novavax on the brink early in 2019 after its respiratory syncytial virus vaccine candidate flunked a late-stage study.The company effected a 1-for-20 reverse split in May 2019 to give a decent look...
As the U.S. continues to feel pressure from the coronavirus, many investors expect companies to tank their earnings. Yahoo Finance’s Dan Howley joins The Final Round panel to break down what to expect from Microsoft’s upcoming Q4 earnings report. ...
Stocks rose Monday as investors looked ahead to a packed week of earnings, stimulus talks and congressional testimony from Covid-19 vaccine developers. The Nasdaq logged a record close after rising 1% as shares of Amazon jumped 5% after Goldman Sachs raised its price target on the e-commerce stock to $3800 from $3000.
...
The number of coronavirus cases continues to climb and grow, worrying local governments and medical professionals. Dr. Howard Forman, Yale School of Public Health Professor, joins The Final Round to offer his insights into the vaccine race, what can be done to reopen more safely, and the latest information about the coronavirus....
